Tirzepatide

Adults: Route of administration Tirzepatide should be administered as a subcutaneous injection. Dosing instructions The recommended starting dosage is 2.5 mg injected subcutaneously once weekly. This 2.5 mg dosage is for starting treatment and is not meant for glycemic control. After 4 weeks, increase the dosage to 5 mg once weekly. If more glycemic control is needed, increase the dosage in 2.5 mg steps, but only after at least 4 weeks on the current dose. The maximum dosage is 15 mg injected subcutaneously once weekly. If a dose is missed, tell the patient to administer it as soon as possible within 4 days (96 hours) after the missed dose. If more than 4 days have passed, skip the missed dose and administer the next dose on the regularly scheduled day. In each case, patients can then go back to their regular once weekly schedule. The day of weekly administration can be changed if necessary, as long as the time between the two doses is at least 3 days (72 hours). Preparation and administration The needle cover of the pre-filled syringe contains dry natural rubber (a derivative of latex), which may cause allergic reactions. Do not freeze, and do not use it if it has been frozen. Protect pre-filled syringes from light. Parenteral drug products should be inspected visually for particulate matter and discoloration before administration, and any pre-filled syringe showing particulate matter or discoloration should not be used. Handle it carefully. If the pre-filled syringe has dropped on a hard surface, do not use it. Do not dilute Tirzepatide, and do not administer it together with other drug solutions. Administration instructions Administer once weekly, any time of day, with or without meals. Inject it subcutaneously in the abdomen, thigh or upper arm, and rotate injection sites with each dose. When using it with insulin, administer them as separate injections and never mix them. It is acceptable to inject the two in the same body region, but the injections should not be adjacent to each other.